Add

The role of microRNA in the development of pulmonary hypertension - Glasgow

MRC Industrial CASE Award
The role of microRNA in the development of pulmonary hypertension

Description

Pulmonary arterial hypertension (PAH) is characterised by obliteration of small pulmonary arteries by smooth muscle and myofibroblast proliferation and endothelial dysfunction. Despite recent therapeutic advances the prognosis remains poor and the molecular basis of PAH remains unclear. MicroRNAs (miRNAs) are small (typically 19-23 nucleotides) non-coding RNAs that control the translation of mRNAs. In lead up studies we have assessed the expression of miRNAs in two commonly used rat models of PAH: chronic hypoxia and induction of PAH by the alkaloid toxin, monocrotaline. Our data confirms regulation of miRNA in these models. We will use a range of approaches to determine the role of defined miRNAs, their target genes and the interconnection between mRNA, miRNA and the proteome. We will address the influence of individual miRNAs on critical signalling pathways implicated in PAH pathobiology (e.g. serotonin, TGF- signalling) by using relevant models.

Value

Stipend rates start from £13,489 and include £3441 towards fees and £300 towards conference and travel.

References

Paola Caruso, Margaret R. MacLean, Raya Khanin, John McClure, Elaine Soon, Mark Southwood, Robert A. McDonald, Jenny A. Greig, Keith E. Robertson, Rachel Masson, Laura Denby, Yvonne Dempsie, Lu Long, Nicholas W. Morrell, and Andrew H. Baker
Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension Due to Chronic Hypoxia and Monocrotaline
Arterioscler Thromb Vasc Biol published January 28, 2010, doi:10.1161/ATVBAHA.109.202028

Eligibility
A first class or 2:1 honours degree in an appropriate discipline.

Deadline
Applications should be made by visiting our website by clicking 'APPLY NOW' by 31st March 2010

Contact
Prof Andrew Baker (a.baker@clinmed.gla.ac.uk) Phone: 0141 330 1977.